The Zacks Analyst Blog Highlights: China Mobile, China Petroleum and Chemical, Trina Solar, AstraZeneca and AmgenThe Zacks Analyst Blog Highlights: China Mobile, China Petroleum and Chemical, Trina Solar, AstraZeneca and Amgen
For Immediate Release
Chicago, IL – June 13, 2014 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the China Mobile Limited (CHL-Free Report), China Petroleum and Chemical Corp. (SNP-Free Report), Trina Solar Limited (TSL-Free Report), AstraZeneca (AZN-Free Report) and Amgen (AMGN-Free Report).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Thursday’s Analyst Blog:
China Stock Roundup
Stocks had a mixed week after concerns surrounding new share sales made a comeback. The benchmark index inched upwards on Monday even as fears over IPOs returned. The Shanghai Composite posted its largest increase in nearly a month on Tuesday following the announcement of several measures intended to boost capital markets.
The introduction of new measures to reduce water pollution led to gains for utilities stocks on Wednesday, pushing the benchmark index upward. Stocks moved lower today ahead of the release of key economic data. China Mobile Limited (CHL-Free Report) acquired a stake in a leading Thai telecom company. Additionally, reports emerged that China Petroleum and Chemical Corp. (SNP-Free Report) had increased its oil output from its Iran project.
Markets and the Economy This Week
Stocks declined on Monday following concerns that new share sales would divert funds from older stocks. Small companies and tech shares led the losses as fears surrounding IPOs returned to haunt markets. Around two stocks took losses for each one that moved up on the benchmark index. The Shanghai Composite Index closed nearly 0.1% higher while the CSI lost less than 0.1%. The Hang China Enterprises Index gained 0.5%. The Bloomberg China-US Equity Index moved up 0.5%.
The Shanghai Composite Index gained 1.1% on Tuesday, its largest increase since May 12. Financial and tech shares led gains after the central bank announced measures to increase lending to smaller companies. Meanwhile, China Securities Regulatory Commission allowed several first time share sales. The rise in export figures for May, announced earlier this week has also provided impetus to the capital markets. The CSI 300 increased 1.3% while the Hang China Enterprises Index gained 1%. The Bloomberg China-US Equity Index moved up 1%.
The benchmark index moved up on Wednesday after utility companies gained following indications that the government will introduce new measures to reduce water pollution. This development outweighed the negative influence of MSCI Inc.’s decision to leave out local shares from global indices.
The Shanghai Composite Index gained 0.1% while the CSI 300 Index closed nearly flat. A sub-index of utility companies increased 0.8%, the highest among the CSI 300’s 10 industry groups. The Hang Seng China Enterprises Index lost 0.2%. The Bloomberg China-US Equity Index declined 0.2%.
Stocks declined today ahead of the release of crucial economic data with consumer discretionary stocks losing the most. The Shanghai Composite Index lost 0.2%. The Shanghai Composite has lost 3% this year, following concerns that an economic slowdown will affect earnings and IPOs will lure funds away from older stocks. The CSI 300 moved down 0.3% while a sub-index of consumer discretionary stocks lost 0.7%, the highest among the index’s 10 industry groups. The Hang Seng China Enterprises Index declined 0.8%.
Stocks in the News
China Petroleum and Chemical Corporation, also known as Sinopec has significantly increased production from its oil project in Iran. Production has increased from 25,000 barrels to 50,000 barrels per day at the company’s Yadvaran project starting early April.
Relations between Iran and China were strained following the cancellation of an oil field deal worth $2.5 billion with China National Petroleum Corp. The increase in production is part of an initiative to improve relations between Iran and China following this incident.
Additionally, the company plans to increased output to 135,000 barrels per day. Such a jump in production comes as a positive development for Iran. The country’s oil production has been severely affected by international sanctions. Crude output had declined 7% in April compared to its 2013 average.
China Mobile Limited has acquired an 18% stake in Thailand’s third largest telecom company True Corp. The world’s largest mobile phone company in terms of carriers bought the stake for 28.6 billion baht ($880 million).
Recently, China Mobile has experienced declining profits in the nation’s increasingly crowded wireless market. Last year, the company’s chairman told investors that it was planning to invest in foreign markets. This is the company’s second key overseas acquisition, after it acquired Pakistan’s Paktel, now called Zong, in 2007.
This acquisition is in keeping with China Mobile’s strategy to use its cash mountain, which exceeds $70 billion, to increase its presence in overseas markets. The deal will also provide opportunities to offer fixed-lined broadband, pay TV and WiFi services. This is because True Corp is already the leading player in these domains in Thailand.
Trina Solar Limited (TSL-Free Report) has raised around $239 million through the sale of convertible senior notes and ADRs. On Wednesday, the company announced it has received an aggregate net amount of around $146.3 million from the sale of convertible notes due in 2019.
In another statement, Trina Solar said that it has mopped up around $92.9 million from the sale of 8.8 million ADRs. Each ADR is worth 50 ordinary shares and the offering was priced at $11 per ADR.
AstraZeneca / Amgen Arthiritis Drug Shows Promise
AstraZeneca (AZN-Free Report) and partner Amgen (AMGN-Free Report) announced that data from a phase II study (n = 168) evaluating the use of brodalumab in patients suffering from psoriatic arthritis was published in The New England Journal of Medicine (:NEJM). The data will also be presented at the annual meeting of the European League Against Rheumatism (:EULAR).
In the randomized, double-blind, placebo-controlled, phase II study, brodalumab demonstrated significant improvement (measured using the American College of Rheumatology score of 20% improvement/ACR20) in signs and clinical symptoms associated with psoriatic arthritis including tender and swollen joints at 12 weeks. It was also found that several patients continued to improve and the improvement was sustained through the first 52 weeks of the study.
Amgen and AstraZeneca are currently conducting two phase III studies (AMVISION-1 and AMVISION-2) evaluating the use of brodalumab in patients suffering from psoriatic arthritis. The study will also assess brodalumab’s ability to prevent joint damage.
Apart from psoriatic arthritis, the companies are evaluating brodalumab for moderate-to-severe plaque psoriasis (phase III) and asthma (phase II).
Both Amgen and AstraZeneca are working on strengthening their product portfolio and brodalumab is one of the key candidates in their pipeline. According to a press release issued by AstraZeneca, analysts estimate peak sales of brodalumab to range between $0.5 billion and $1.5 billion.
Amgen and AstraZeneca are both Zacks Rank #3 (Hold) stocks.
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.
Get the full Report on CHL - FREE
Get the full Report on SNP - FREE
Get the full Report on TSL - FREE
Get the full Report on AZN - FREE
Get the full Report on AMGN - FREE
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Read the analyst report on CHL
Read the analyst report on SNP
Read the analyst report on TSL
Read the analyst report on AZN
Read the analyst report on AMGN
Zacks Investment Research
